8 Top Gainers In Pharma Sector (NOVN, TNXP, KOD...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Novan Inc. (NOVN)

Gained 24.19% to close Wednesday's (May 22) trading at $2.31.

News: No news

Clinical Trials & Near-term Catalyst:

The Company's lead asset is SB206, a phase III-ready compound for the treatment of molluscum contagiosum.

The phase III molluscum program will begin recruiting patients this month (May) with top-line results targeted early during the first quarter of 2020 or before.

Molluscum contagiosum is a common skin disease caused by a virus and is characterized by pink or flesh-colored bumps on the skin (Source: American Academy of Dermatology).

A phase II study of SB414 in Atopic Dermatitis is expected to be initiated in the fourth quarter of 2019.

2. Tonix Pharmaceuticals Holding Corp. (TNXP)

Gained 19.41% to close Wednesday's trading at $2.03.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase III study of Tonmya 5.6 mg for the treatment of posttraumatic stress disorder, dubbed RECOVERY, is underway - with topline data expected in the first half of 2020.

3. vTv Therapeutics Inc. (VTVT)

Gained 13.66% to close Wednesday's trading at $1.83.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase 2 trial evaluating TTP399 as an add-on to insulin therapy for patients with type 1 diabetes, dubbed Simplici-T1 Study, is underway - with results from part 1 of the study expected in June 2019. -- Screening for Phase 2 clinical trial of Azeliragon in the treatment of mild- Alzheimer's disease in patients with type 2 diabetes is expected to begin in June 2019.

4. Xtant Medical Holdings Inc. (XTNT)

Gained 13.49% to close Wednesday's trading at $3.45.

Xtant Medical is a commercial-stage global medical technology company focused on surgical solutions for the treatment of spinal disorders.

News: No news

Recent event:

On May 15, 2019, the Company reported financial and operating results for the first quarter ended March 31, 2019.

The net loss for the first quarter of 2019 narrowed to $2.8 million or $0.21 per share from $5.3 million or $0.70 per share in the year-ago comparable period. First quarter 2019 revenue was $16.7 million, compared to $17.9 million for the same period in 2018. The decrease occurred primarily due to lower sales in the spinal hardware implant product line.

5. Allied Healthcare Products Inc. (AHPI)

Allied Healthcare is a manufacturer of medical gas construction equipment, respiratory therapy equipment, home healthcare products, and emergency medical supplies.

Gained 12.84% to close Wednesday's trading at $1.67.

News: No news

6. INmune Bio Inc. (INMB)

Gained 12.63% to close Wednesday's trading at $10.70.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase I combination therapy of INB03 in patients with advanced solid tumors is expected to be initiated this summer. -- A phase I/II trial of INKmune in women with relapsed refractory ovarian cancer is expected to start enrolling patients later this year. -- A phase I trial of XPro1595 in patients with Alzheimer's disease is slated to enroll its first patient this summer.

7. Kodiak Sciences Inc. (KOD)

Gained 12.53% to close Wednesday's trading at $10.24.

News: No news

Clinical Trials & Near-term Catalysts:

-- A Phase 1b multiple-dose study of KSI-301 in patients with wet AMD, diabetic macular edema, and retinal vein occlusion is underway, with data expected in the second half of 2019. -- A phase II head-to-head study of KSI-301 against Regeneron's Eylea (aflibercept) in patients with wet AMD is expected to be initiated this year.

8. Guardion Health Sciences Inc. (GHSI)

Guardion Health is an ocular health sciences and technologies company.

Gained 11.87% to close Wednesday's trading at $1.79.

News: No news

Recent event:

The Company went public on the Nasdaq Capital Market on April 5, 2019, offering its shares at a price of $4 each.

Portfolio:

The Company markets a medical food product under the brand name Lumega-Z that replenishes and restores the macular protective pigment in conditions such as age-related macular degeneration ("AMD"), computer vision syndrome ("CVS") and diabetic retinopathy.

Another product in the kitty is a proprietary medical device called the MapcatSF that accurately measures the macular pigment optical density. The device is currently classified by the FDA as a Class I medical device which does not require pre-market approval.